Goldman Sachs upgraded Novo Nordisk (NYSE: NVO) from Neutral to Buy with a 740 Dkr price target, representing upside of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE